Search

Message from the EHA President

As the year closes, is with great pleasure that I reflect on 2021, six months into my Presidency of the European Hematology Association (EHA). It is also time to look forward to the new year.

Read more

Multi-center acute myeloid leukemia study update, December 2023

A project update from Prof Maria Teresa Voso. We successfully completed the data collection and harmonization phases, and are now in the process of data analysis.

Read more

EHA-Balkan Hematology Day 2023

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 4th edition of the EHA-Balkan Hematology Day.

Read more

EHA reaffirms commitment to hematology's future with new brand identity

The European Hematology Association (EHA) is thrilled to announce the launch of our new brand identity. This includes a refreshed logo, updated color palette, and a new slogan, marking a significant milestone in our journey.

Read more

Specialized Working Groups

EHA partners with Specialized Working Groups (SWGs) to foster science and to spread knowledge in basic, translational and clinical research in hematology in Europe.

Read more

Sponsor prospectus

Dear Partner,

Welcome to the digital EHA Sponsor Prospectus 2024-2025. Over the past two years, the world of congresses, meetings, and education has drastically changed.

Read more

EHA-EMBL/EBI Computational Biology Training in Hematology

The CBTH 2025 call for applications is now closed.

Read more

Kite and Gilead @EHA25 Virtual

We are proud to support the first ever EHA25 Virtual congress. Please join us & leading experts to learn about the latest in cell therapies and COVID-19.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013

Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.

Read more